GlaxoSmithKline Pharmaceuticals Limited — Board Meeting, 13-05-2025: Outcome of Board Meeting

GlaxoSmithKline Pharmaceuticals has announced a board meeting on approving consolidated financial results for the quarter and year ended March 31, 2025. Revenue rose to ₹3895 Cr, with profit after tax surging to ₹927.6 Cr from ₹590 Cr last year. A final dividend of ₹42 per share was declared, up from ₹32. Dr. Sunita Maheshwari was re-appointed as Independent Director for three years. Parikh & Associates will serve as Secretarial Auditor for five years starting FY26. The company continues to deliver steady pharma operations and strong cash flow.